China Medical System (HKG:0867, SGX:8A8) was granted an approval for its Silevimig Injection, an antibody aimed at providing immunity against rabies, according to a Monday filing with the Singapore Exchange.
The approval, which was secured by China's National Medical Products Administration, will now lead the way for manufacturing at scale, with the treatment option available for patients requiring urgent post-exposure management against rabies.